Literature DB >> 2088769

In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. II. Vinblastine and vincristine.

X J Zhou1, M Martin, M Placidi, J P Cano, R Rahmani.   

Abstract

Vinblastine and Vincristine pharmacokinetics, including tissue distribution, metabolism and biliary excretion, were investigated, using both "in vitro" and "in vivo" models, after i.v. injections in rats. Plasma kinetic curves were best fitted to a two-compartment open model. The average terminal half-lives of VLB and VCR were 14.3 h and 7.5 h, respectively. The systemic clearance and apparent distribution volume for VLB, respectively 1.49 l/h/kg and 11.46 l/kg, were significantly greater than those of VCR, 0.12 l/h/kg and 0.41 l/kg. VCR was found to be widely distributed in tissues after i.v. injections in rats. The highest drug accumulation site was the intestine (122.0 ng/g wet tissue at 24 h). Liver and kidneys also retained high proportions of drug (respectively, 47.0 ng/g and 44.4 ng/g at 24 h). Biliary excretion was more rapid for VCR (42.7% of total radioactivity excreted over 24 h) than VLB (28.2% of total dose over 24 h). For both molecules, the percentage of radioactivity excreted in bile over 30-48 h ranged between 40-50% of total dose. At high doses, either biliary excretion rate or cumulated excretion was reduced. High performance liquid chromatography analysis of bile samples revealed four biotransformation products for VLB and three for VCR. When incubated in freshly isolated rat hepatocytes, VLB penetrated more rapidly and intensely into the cells (more than 90% of total dose taken up over 20 min) than VCR (only about 40% accumulated), probably through a passive diffusion mechanism followed by tight cellular binding. "In vitro" metabolism patterns were similar to those found "in vivo", except for the most polar metabolites observed "in vitro". Two anti-Vinca monoclonal antibodies with different specificities were used to test VCR metabolite immunoreactivities. The results suggested that some structural modifications occurred in the catharantine moiety of the molecule but that the dimeric structure seemed to be well conserved after biotransformation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2088769     DOI: 10.1007/BF03190222

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  16 in total

1.  Interpatient and intrapatient variability in vinblastine pharmacokinetics.

Authors:  M J Ratain; N J Vogelzang; J A Sinkule
Journal:  Clin Pharmacol Ther       Date:  1987-01       Impact factor: 6.875

2.  Conversational SAAM--an interactive program for kinetic analysis of biological systems.

Authors:  R C Boston; P C Greif; M Berman
Journal:  Comput Programs Biomed       Date:  1981 Mar-Jun

3.  Distribution and excretion of (3H)vincristine in the rat and the dog.

Authors:  M C Castle; D A Margileth; V T Oliverio
Journal:  Cancer Res       Date:  1976-10       Impact factor: 12.701

4.  A 125I-radiolabelled probe for vinblastine and vindesine radioimmunoassays: applications to measurements of vindesine plasma levels in man after intravenous injections and long-term infusions.

Authors:  R Rahmani; J Barbet; J P Cano
Journal:  Clin Chim Acta       Date:  1983-03-28       Impact factor: 3.786

5.  Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine.

Authors:  J A Young; S B Howell; M R Green
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

6.  Clinical pharmacokinetics of vindesine: repeated treatments by intravenous bolus injections.

Authors:  R Rahmani; M Martin; R Favre; J P Cano; J Barbet
Journal:  Eur J Cancer Clin Oncol       Date:  1984-11

7.  Pharmacokinetics of vincristine infusion.

Authors:  D V Jackson; V S Sethi; C L Spurr; D R White; F Richards; J J Stuart; H B Muss; M R Cooper; M C Castle
Journal:  Cancer Treat Rep       Date:  1981 Nov-Dec

8.  Clinical pharmacokinetics of the antitumor drug navelbine (5'-noranhydrovinblastine).

Authors:  R Rahmani; R Bruno; A Iliadis; R Favre; S Just; J Barbet; J P Cano
Journal:  Cancer Res       Date:  1987-11-01       Impact factor: 12.701

9.  The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination.

Authors:  H W Van den Berg; Z R Desai; R Wilson; G Kennedy; J M Bridges; R G Shanks
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  High-yield preparation of isolated rat liver parenchymal cells: a biochemical and fine structural study.

Authors:  M N Berry; D S Friend
Journal:  J Cell Biol       Date:  1969-12       Impact factor: 10.539

View more
  9 in total

1.  Role of the OATP Transporter Family and a Benzbromarone-SensitiveEfflux Transporter in the Hepatocellular Disposition of Vincristine.

Authors:  Johan Nicolaï; Louise Thevelin; Qi Bing; Bruno Stieger; Hugues Chanteux; Patrick Augustijns; Pieter Annaert
Journal:  Pharm Res       Date:  2017-08-21       Impact factor: 4.200

2.  Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2.

Authors:  Nicola F Smith; Sridhar Mani; Erin G Schuetz; Kazuto Yasuda; Tristan M Sissung; Susan E Bates; William D Figg; Alex Sparreboom
Journal:  Ann Pharmacother       Date:  2010-10-19       Impact factor: 3.154

3.  Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high-performance liquid chromatography.

Authors:  O van Tellingen; J H Beijnen; W J Nooijen; A Bult
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 4.  Preclinical and clinical pharmacology of vinca alkaloids.

Authors:  X J Zhou; R Rahmani
Journal:  Drugs       Date:  1992       Impact factor: 9.546

5.  Nociceptor hyper-responsiveness during vincristine-induced painful peripheral neuropathy in the rat.

Authors:  K D Tanner; D B Reichling; J D Levine
Journal:  J Neurosci       Date:  1998-08-15       Impact factor: 6.167

6.  Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography.

Authors:  O van Tellingen; A V Kuijpers; J H Beijnen; W J Nooijen; A Bult
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

7.  Hyperlipidemia Alters the Pharmacokinetics of Posaconazole and Vincristine Upon Co-Administration in Rats.

Authors:  Hadeel A Khalil; Mohammed A W ElKhatib; Tarek S Belal; Ahmed F El-Yazbi; Dalia A Hamdy
Journal:  Drugs R D       Date:  2017-06

8.  High Performance Liquid Chromatographic Assay for the Simultaneous Determination of Posaconazole and Vincristine in Rat Plasma.

Authors:  Hadeel A Khalil; Ahmed F El-Yazbi; Tarek S Belal; Dalia A Hamdy
Journal:  Int J Anal Chem       Date:  2015-12-22       Impact factor: 1.885

9.  The effect of increased lipoproteins levels on the disposition of vincristine in rat.

Authors:  Hadeel A Khalil; Tarek S Belal; Ahmed F El-Yazbi; Dalia A Hamdy
Journal:  Lipids Health Dis       Date:  2016-09-09       Impact factor: 3.876

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.